Suven Pharmaceuticals is trading -0.03% lower at Rs 1,006.35 as compared to its last closing price. Suven Pharmaceuticals has been trading in the price range of 1,018.00 & 1,002.45. Suven Pharmaceuticals has given -11.34% in this year & 0.73% in the last 5 days. Suven Pharmaceuticals has TTM P/E ratio 109.31 as compared to the sector P/E of 22.82.There are 6 analysts who have initiated coverage on Suven Pharmaceuticals. There are 3 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 38.73 Crores in its last quarter.Listed peers of Suven Pharmaceuticals include Glenmark Pharmaceuticals (-1.54%), Biocon (2.29%), Suven Pharmaceuticals (-0.03%).The Mutual Fund holding in Suven Pharmaceuticals was at 8.65% in 9 May 2025. The MF holding has increased from the last quarter. The FII holding in Suven Pharmaceuticals was at 7.38% in 9 May 2025. The FII holding has increased from the last quarter.
Updated on Jun 19, 2025, 05:54 AM UTC
|
|
|
|
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
---|---|---|---|---|---|---|---|---|
Glenmark Pharmaceuticals | Bullish | 1,634.55 | -1.54 | 46,127.13 | 35.18 | 5.27 | 0.15 | 7.90 |
Biocon | Bullish | 350.00 | 2.29 | 42,021.00 | 44.93 | 1.96 | 0.14 | 59.81 |
Suven Pharmaceuticals | Bearish | 1,006.35 | -0.03 | 38,289.40 | 95.22 | 14.93 | - | 10.36 |
Laurus Labs | Bullish | 658.80 | -0.69 | 35,720.62 | 112.59 | 7.96 | 0.18 | 15.82 |
Ipca Laboratories | Bearish | 1,348.15 | -1.05 | 34,198.06 | 39.16 | 4.96 | 0.29 | 8.55 |
Meeting Date | Purpose |
---|---|
2025-05-28 | Audited Results |
2025-02-12 | Quarterly Results |
2024-11-12 | Quarterly Results |
2024-08-09 | Quarterly Results |
2024-05-30 | Audited Results |
Suven Pharmaceuticals is trading at 1006.35 as on Thu Jun 19 2025 05:47:50. This is -0.03% lower as compared to its previous closing price of 1006.70.
The market capitalization of Suven Pharmaceuticals is 38289.40 Cr as on Thu Jun 19 2025 05:47:50.
The average broker rating on Suven Pharmaceuticals is Strong Buy. The breakup of analyst rating is given below -
The 52 wk high for Suven Pharmaceuticals is 1359.00 whereas the 52 wk low is 696.55
Suven Pharmaceuticals can be analyzed on the following key metrics -
Suven Pharmaceuticals reported a net profit of 264.77 Cr in 2025.
The Mutual Fund Shareholding was 8.65% at the end of 9 May 2025.